Board of Directors
Our Board of Directors brings unparalleled expertise and insight, guiding our mission to revolutionize health and nutrition. They embody our core values of innovation, integrity, and excellence, ensuring our strategies not only meet but exceed industry standards.
Their collective experience shapes our approach to precision nutrition, driving us to deliver scientifically validated, trustworthy solutions. Under their leadership, Chrysea is forging a path towards a healthier future, making impactful strides in wellness and preventive health.
-
Dr. Richard Marshall, CBE, MD, PhD
Non-Executive Director
Dr. Richard Marshall, CBE, MD, PhD LinkedInDr. Richard Marshall is a physician scientist and a highly experienced executive with over 20-year track record of outstanding leadership in Pharmaceutical R&D. He is driven by a passion for developing new medicines to treat diseases of high unmet need and is excited to lead Juvenescence as CEO, on its mission to improve the healthspan of people globally.
Most recently, Richard was Senior Vice President and Global Head of Respiratory & Immunology Development at AstraZeneca, overseeing the development and approval of five new medicines. This included the SARS CoV-2 vaccine, Vaxzevria, and combination antibody, Evusheld. In 2021 he was recognized in the Queen’s Honours List with a CBE for his contribution to UK science and the Covid response.
Before joining AstraZeneca, Richard held increasingly senior roles at GlaxoSmithKline and was Vice President of Fibrosis R&D. He trained at UCL and has held visiting professor and honorary consultant roles in thoracic medicine at Newcastle University and the Royal Brompton Hospital. Throughout his career, Richard has co-authored >60 original publications in journals including The Lancet and The New England Journal of Medicine.
-
Pedro de Noronha Pissarra, PhD
Chief Executive Officer
Pedro de Noronha Pissarra, PhD LinkedInPedro is an established, highly-networked and seasoned life-sciences entrepreneur, with over 25-years track record in the biotechnology and healthcare industry.
A graduate from Kings College London he carried out research at Massachusetts Institute of Technology (MIT), the Technical University of Denmark (DTU), and Técnico Lisbon (IST); He further took a 12-months Masters Programme in Management at the University of Texas, Austin. He Founded in 1996 and sold in 2018 the Biotecnol Group of companies, RDN (biopharmaceutical products CDMO company sold to the Iberfar Group) and Biotecnol Limited (a pioneering immuno-oncology company, Sold to Chiome, Inc). Pedro was a Board Member of Vida Rhein SA, part of the Rhein Biotech NV group, developing hepatitis vaccines (sold to Dynavax, Inc) and Board Member of 4Tune Engineering, a Portuguese leading data-analytics and risk-analysis company (sold to Valgenesis, Inc). With a deal flow of over €250M in financing and transactions, including fund-raising, deal-making, M&A, Pedro brings a wealth of experience from an entrepreneurial and leadership perspective across the various components of a biotech company value-chain.
Pedro has collected over the years numerous awards for his pioneering achievements in bioentrepreneurship.